Endocrine Abstracts

Introduction: Sodium/glucose co-transporter 2 (SGLT2) inhibitors are a relatively new group of antihyperglycaemic medications for type 2 diabetes mellitus (T2DM). Euglycemic diabetic ketoacidosis (EDKA) and Fournier’s gangrene (FG) are uncommon advers effects of SGLT2 inhibitors. We report a case of a 52-year-old man who developed FG and EDKA after starting the SGLT2 inhibitor empagliflozin.Case Presentation: A-52 years old male patient attended to ...

Introduction: Sodium/glucose co-transporter 2 (SGLT2) inhibitors are novel oral hypoglycemic agents that are increasingly used in the management of type 2 diabetes mellitus (T2DM). They are now recommended as second-line pharmacotherapy (in conjunction with metformin) in patients with type 2 diabetes and established atherosclerotic heart disease, heart failure or chronic kidney disease due to their favourable effects on cardiovascular and renal outcomes. We report a case of a ...

Introduction: Insulin antibodies, developed in patients treated with exogenous insulin, might affect glycemic control due to their tendency to bind and/or release insulin in an unpredictable fashion. It is reported to be caused by immunoglobulin G-derived insulin antibodies. Insulin antibodies induced by exogenous insulin in diabetic patients is associated with hypersensitivity reactions, glycemic variability mainly with insulin resistance/ hyperglycemia or hypoglycemia. We re...

Introduction: The only curative treatment of primary hyperparathyroidism (pHPT) is surgery. Accurate pre-operative localization of abnormal parathyroid glands is an essential prerequisite to reduce the complication risk associated with surgery. We aimed to determine the diagnostic value of jugular venous sampling (JVS) in cases of pHPT in which the location of parathyroid adenomas could not be determined through various preoperative imaging studies.Metho...

Introduction: Primary hyperparathyroidism (pHPT) is the third most frequently seen endocrine disease with autonomous overproduction of parathyroid hormone (PTH) in one or more parathyroid glands. It’s associated with osteoporosis, bone fractures, nephrolithiasis, renal failure and increased cardiovascular risk. We aimed to investigate the distribution of the clinical manifestations and biochemical features in patients with pHPT.Methods: A retrospect...